# Andrew Gottesdiener

> Andrew Gottesdiener is a seed investor at Venrock (New York) backing Health Care and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Venrock](https://shizune.co/investors/profile/venrock)
- Location: New York, United States
- Total investments: 3
- Last investment: Jun 2026
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/agottesdiener/
- Website: https://www.venrock.com/teammember/andrew-gottesdiener/

Andrew Gottesdiener is a seed investor at Venrock in New York focused on Health Care and Biotechnology. Andrew Gottesdiener is based out of New York, New York, and is the Partner of Venrock and Board of Director at Korsana Biosciences. Andrew Gottesdiener attended Washington University in St. Louis.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Biopharma | 1 | 33% |
| Life Science | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series C | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lycia Therapeutics | Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M | Series D | Jun 25, 2026 |  |
| Lycia Therapeutics | Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $106.6M | Series C | May 13, 2024 |  |
| Korsana Biosciences | Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications. | $25M | Seed | Jan 01, 2024 |  |

3 of 3 investments shown.

## Co-investors
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 2 deals together
- [Franklin Templeton](https://shizune.co/investors/profile/franklin-templeton-investments) — VC Fund, 2 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 2 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 2 deals together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 2 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together

## About Venrock

VC Fund · Palo Alto, United States

Venrock continues a tradition of partnering with entrepreneurs to establish successful, enduring companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Nest, SlideShare,and Tudou.

5 contacts available at Venrock.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew Gottesdiener | Partner | https://shizune.co/investors/profile/andrew-gottesdiener-91c0 |
| Anthony Evnin | Partner Emeritus | https://shizune.co/investors/profile/anthony-evnin |
| Bryan Roberts | Partner | https://shizune.co/investors/profile/bryan-e-roberts |
| Mariana Mihalusova | Vice President | https://shizune.co/investors/profile/mariana-mihalusova-65b2 |
| Mike Tyrrell | General Partner | https://shizune.co/investors/profile/mike-tyrrell |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Andrew Gottesdiener invest in?

Andrew Gottesdiener invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andrew Gottesdiener last invest?

The most recent investment recorded for Andrew Gottesdiener closed in Jun 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co